The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
September 14th 2024
Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.
DZD1516 Demonstrates Safety, Early Activity in Heavily Pretreated Metastatic HER2+ Breast Cancer
DZD1516 monotherapy elicited early clinical activity and was found to be well tolerated in patients with HER2-positive metastatic breast cancer with or without brain metastases.
Pyrotinib Plus Trastuzumab/Docetaxel Prolongs PFS in HER2+ Metastatic Breast Cancer
The addition of pyrotinib to trastuzumab and docetaxel significantly improved progression-free survival vs trastuzumab/docetaxel alone in patients with HER2-positive metastatic breast cancer.
Zanidatamab Zovodotin Showcases Promising Safety, Activity in HER2+ Solid Cancers
Zanidatamab zovodotin was found to produce encouraging responses and to have a manageable toxicity profile when used as a monotherapy in heavily pretreated patients with HER2-positive solid cancers.
Metastatic Breast Cancer Enters a New Era of HER2 Classification
A dramatic presentation at the 2022 American Society of Clinical Oncology Annual Meeting changed treatment standards seemingly overnight for women with previously treated metastatic HER2-low breast cancer. However, fundamental questions remain.
The United Kingdom Medicines and Healthcare Products Regulatory Agency has extended the conditional marketing authorization of fam-trastuzumab deruxtecan-nxki for single-agent use in adult patients in Great Britain who have HER2-positive unresectable or metastatic breast cancer and have received 1 or more prior HER2-based regimens.
Trastuzumab Deruxtecan Shakes Up Treatment Possibilities for HER2-Low Metastatic Breast Cancer
Katherine Tkaczuk, MD, discusses practice-changing data across breast cancer subtypes that were discussed at the 2022 ASCO Annual Meeting, including data from DESTINY-Breast04 and the phase 3 PALOMA-2 trial, plus the utilization of CDK4/6 inhibitors and PARP inhibitors for select patients with breast cancer.
Treatment Strategies Evolve With Increased Disease Specification in HER2+ Breast Cancer
July 15th 2022Adrienne G. Waks, MD, highlights clinical trials that are studying emerging treatment escalation and de-escalation strategies in early stage HER2-positive breast cancer, elaborates on the future of immunotherapy in this setting, and explains the significance of establishing new biomarkers.
Stearns Elaborates on the Evolution of ADCs in HER2+ and HER2-Low Breast Cancer
Vered Stearns, MD, FASCO, discusses how DESTINY-Breast04 has shifted the treatment paradigm for patients with HER2-low breast cancer, the exploration of treatment combinations being optimized in breast cancer, and the expansion of the treatment paradigm in triple-negative breast cancer.
Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer
Adding atezolizumab to neoadjuvant standard of care therapy for HER2-positive early breast cancer did not result in a better pathologic complete response compared with placebo, according to findings from the phase 3 IMpassion050 trial.
Stanford Faculty Break Down Advancements in Women’s Cancer Care
Advancements in treatment options across the spectrum on women’s cancers include de-escalating therapy in HER2-positive breast cancer, using tisotumab vedotin-tftv in cervical cancer, shifting therapies to the frontline setting in endometrial cancer, and using checkpoint inhibitors in ovarian cancer.
HER2 Expression Is a Key Determinant of Trastuzumab Deruxtecan Activity
HER2 expression appeared to be a significant predictor for response to fam-trastuzumab deruxtecan-nxki, according to findings from a biomarker analysis of patients with metastatic breast cancer in the phase 2 DAISY trial.
Trastuzumab Deruxtecan Maintains QOL and Global Health Status in HER2+ Metastatic Breast Cancer
Overall health status and quality of life were maintained among patients with HER2-positive metastatic breast cancer who were treated with fam-trastuzumab deruxtecan-nxki compared with those who received ado-trastuzumab emtansine.
Neoadjuvant and Adjuvant Therapy Elicit Similar Efficacy in Early-Stage HER2+ Breast Cancer
Neoadjuvant therapy generated similar benefits to adjuvant therapy in patients with early-stage, HER2-positive breast cancer treated in China, suggesting that neoadjuvant therapy should be used in this patient population.